{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:36:07Z","timestamp":1772120167864,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002954","name":"Universit\u00e0 degli Studi di Milano - Bicocca","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002954","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40292-021-00450-0","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T11:22:39Z","timestamp":1618226559000},"page":"309-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Elevated Ambulatory Blood Pressure Measurements are Associated with a Progressive Form of Fabry Disease"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1509-1190","authenticated-orcid":false,"given":"Federica","family":"Rossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einar","family":"Svarstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Elsaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Binaggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Roggero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Auricchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Marti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pieruzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"450_CR1","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"450_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"450_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","volume":"121","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler T, Kasper DC, Desnick RJ. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease. Mol Genet Metab. 2017;121:320\u20134.","journal-title":"Mol Genet Metab"},{"key":"450_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1750-1172-4-21","volume":"4","author":"B Hoffmann","year":"2009","unstructured":"Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009;4:21.","journal-title":"Orphanet J Rare Dis"},{"key":"450_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51:1\u20139.","journal-title":"J Med Genet"},{"issue":"4","key":"450_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2215\/CJN.09480819","volume":"15","author":"E Svarstad","year":"2020","unstructured":"Svarstad E, Marti HP. The changing landscape of Fabry disease. Clin J Am Soc Nephrol. 2020;15(4):569\u201376.","journal-title":"Clin J Am Soc Nephrol."},{"key":"450_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","volume":"19","author":"J Kleinert","year":"2006","unstructured":"Kleinert J, et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens. 2006;19:782\u20137.","journal-title":"Am J Hypertens"},{"key":"450_CR8","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","volume":"23","author":"A Ortiz","year":"2008","unstructured":"Ortiz A, et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23:1600\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"450_CR9","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102\u201311.","journal-title":"Nephrol Dial Transplant"},{"key":"450_CR10","doi-asserted-by":"publisher","first-page":"c43","DOI":"10.1159\/000320903","volume":"118","author":"G Jain","year":"2011","unstructured":"Jain G, Warnock DG. Blood pressure, proteinuria and nephropathy in Fabry disease. Nephron Clin Pract. 2011;118:c43\u20138.","journal-title":"Nephron Clin Pract"},{"key":"450_CR11","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1016\/j.ijcard.2012.06.069","volume":"167","author":"W Terryn","year":"2013","unstructured":"Terryn W, et al. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol. 2013;167:2555\u201360.","journal-title":"Int J Cardiol"},{"key":"450_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine. 2002;81:122\u201338.","journal-title":"Medicine"},{"key":"450_CR13","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1016\/j.amjhyper.2004.03.549","volume":"17","author":"G Sunderplassmann","year":"2004","unstructured":"Sunderplassmann G. Uncontrolled hypertension in Fabry disease. Am J Hypertens. 2004;17:S206.","journal-title":"Am J Hypertens"},{"key":"450_CR14","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1097\/HJH.0000000000001961","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:2284\u2013309.","journal-title":"J Hypertens"},{"key":"450_CR15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/kisup.2012.77","volume":"3","author":"G Eknoyan","year":"2013","unstructured":"Eknoyan G, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:5\u201314.","journal-title":"Kidney Int."},{"key":"450_CR16","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"RM Lang","year":"2005","unstructured":"Lang RM, et al. Recommendations for Chamber Quantification: a report from the American Society of Echocardiography\u2019s guidelines and standards committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440\u201363.","journal-title":"J Am Soc Echocardiogr"},{"key":"450_CR17","first-page":"1969","volume-title":"Hypertension: Pathophysiology, Diagnosis, Management","author":"RB Devereux","year":"1995","unstructured":"Devereux RB, Roman MJ. Evaluation of cardiac and vascular structure by echocardiography and other noninvasive techniques. In: Laragh JH, Brenner BM, editors. Hypertension: Pathophysiology, Diagnosis, Management, 2nd ed. New York: Raven Press; 1995. p. 1969\u201385.","edition":"2,"},{"key":"450_CR18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/00004872-199715090-00010","volume":"15","author":"PB Clarkson","year":"1997","unstructured":"Clarkson PB, Prasad N, MacLeod C, Burchell B, MacDonald TM. Influence of the angiotensin converting enzyme I\/D gene polymorphisms on left ventricular diastolic filling in patients with essential hypertension. J Hypertens. 1997;15:995\u20131000.","journal-title":"J Hypertens"},{"key":"450_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ckj\/sfw082","volume":"9","author":"R Mignani","year":"2016","unstructured":"Mignani R, et al. FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease. Clin Kidney J. 2016;9:739\u201347.","journal-title":"Clin Kidney J"},{"key":"450_CR20","unstructured":"Fastex 2.0 Home page. https:\/\/www.fastex.online. Accessed Jan 2020."},{"key":"450_CR21","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.ymgme.2016.11.082","volume":"120","author":"RJ Desnick","year":"2017","unstructured":"Desnick RJ, Chen R, Srinivasan R, Doheny DO, Bishop D. The Fabry disease genotype\u2013phenotype database (dbFGP): an international expert consortium. Mol Genet Metab. 2017;120:S41\u20132.","journal-title":"Mol Genet Metab"},{"key":"450_CR22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/mgg3.389","volume":"6","author":"DP Germain","year":"2018","unstructured":"Germain DP, et al. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study. Mol Genet Genom Med. 2018;6:492\u2013503.","journal-title":"Mol Genet Genom Med"},{"key":"450_CR23","unstructured":"Mutation Search. http:\/\/www.dbfgp.org\/dbFgp\/fabry\/Mutation.html. Accessed Jan 2020."},{"key":"450_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.18865\/ed.26.3.279","volume":"26","author":"K Mezue","year":"2016","unstructured":"Mezue K, et al. Nocturnal non-dipping blood pressure profile in black normotensives is associated with cardiac target organ damage. Ethn Dis. 2016;26:279\u201384.","journal-title":"Ethn. Dis."},{"key":"450_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2215\/CJN.02590220","volume":"15","author":"PI Georgianos","year":"2020","unstructured":"Georgianos PI, Agarwal R. Ambulatory BP phenotypes and their association with target organ damage and clinical outcomes in CKD. Clin J Am Soc Nephrol. 2020;15:441\u20133.","journal-title":"Clin J Am Soc Nephrol"},{"key":"450_CR26","first-page":"866","volume":"107","author":"RE Schmieder","year":"2010","unstructured":"Schmieder RE. End organ damage in hypertension. Dtsch Arztebl Int. 2010;107:866\u201373.","journal-title":"Dtsch Arztebl Int"},{"key":"450_CR27","doi-asserted-by":"publisher","first-page":"100565","DOI":"10.1016\/j.ymgmr.2020.100565","volume":"22","author":"O Azevedo","year":"2020","unstructured":"Azevedo O, et al. Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation. Mol Genet Metab Rep. 2020;22:100565.","journal-title":"Mol Genet Metab Rep"},{"key":"450_CR28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/jch.12711","volume":"18","author":"G Tocci","year":"2016","unstructured":"Tocci G, et al. Trends in prevalence, awareness, treatment, and control of blood pressure recorded from 2004 to 2014 during world hypertension day in Italy. J Clin Hypertens. 2016;18:551\u20136.","journal-title":"J. Clin. Hypertens."},{"key":"450_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00041552-200503000-00002","volume":"14","author":"DG Warnock","year":"2005","unstructured":"Warnock DG. Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens. 2005;14:87\u201395.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"450_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2215\/CJN.08840719","volume":"15","author":"SE Mwasongwe","year":"2020","unstructured":"Mwasongwe SE, et al. Ambulatory blood pressure phenotypes in adults taking antihypertensive medication with and without CKD. Clin J Am Soc Nephrol. 2020;15:501\u201310.","journal-title":"Clin J Am Soc Nephrol"},{"key":"450_CR31","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"450_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","volume":"99","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, et al. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010;99:99\u2013108.","journal-title":"Mol Genet Metab"},{"key":"450_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","volume":"47","author":"T DeGraba","year":"2000","unstructured":"DeGraba T, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000;47:229\u201333.","journal-title":"Ann Neurol"},{"key":"450_CR34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/jcb.1198","volume":"82","author":"C Napoli","year":"2001","unstructured":"Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem. 2001;82:674\u201382.","journal-title":"J Cell Biochem"},{"key":"450_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017;122:19\u201327.","journal-title":"Mol Genet Metab"},{"key":"450_CR36","first-page":"358","volume":"19","author":"A Baradaran","year":"2014","unstructured":"Baradaran A, Nasri H, Rafieian-Kopaei M. Oxidative stress and hypertension: possibility of hypertension therapy with antioxidants. J Res Med Sci. 2014;19:358\u201367.","journal-title":"J Res Med Sci"},{"issue":"Suppl 2","key":"450_CR37","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","volume":"13","author":"J Alroy","year":"2002","unstructured":"Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol. 2002;13(Suppl 2):S134\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"450_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1053\/j.ackd.2014.12.001","volume":"22","author":"E Judd","year":"2015","unstructured":"Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015;22:116\u201322.","journal-title":"Adv Chronic Kidney Dis."},{"key":"450_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1254\/jphs.12R03CR","volume":"120","author":"PCJL Santos","year":"2012","unstructured":"Santos PCJL, Krieger JE, Pereira AC. Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications. J Pharmacol Sci. 2012;120:77\u201388.","journal-title":"J Pharmacol Sci"},{"key":"450_CR40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.5414\/CNP63394","volume":"63","author":"E Svarstad","year":"2005","unstructured":"Svarstad E, et al. Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry\u2019s disease. Clin Nephrol. 2005;63:394\u2013401.","journal-title":"Clin Nephrol"},{"key":"450_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5414\/CN109349","volume":"90","author":"W Zhou","year":"2018","unstructured":"Zhou W, Ni Z, Zhang M. Hemizygous Fabry disease associated with membranous nephropathy: a rare case report. Clin Nephrol. 2018;90:227\u201331.","journal-title":"Clin Nephrol"},{"key":"450_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2369-14-6","volume":"14","author":"D Maixnerov\u00e1","year":"2013","unstructured":"Maixnerov\u00e1 D, et al. The coincidence of IgA nephropathy and Fabry disease. BMC Nephrol. 2013;14:6.","journal-title":"BMC Nephrol."},{"key":"450_CR43","doi-asserted-by":"publisher","first-page":"e16256","DOI":"10.1097\/MD.0000000000016256","volume":"98","author":"H Ren","year":"2019","unstructured":"Ren H, et al. Fabry disease and immunoglobulin A nephropathy presenting with Alport syndrome-like findings: a case report. Medicine. 2019;98:e16256.","journal-title":"Medicine"},{"key":"450_CR44","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/S0149-2918(10)00268-7","volume":"32","author":"MJ Hilz","year":"2010","unstructured":"Hilz MJ. Autonomic dysfunction in Fabry disease. Clin Ther. 2010;32:S93.","journal-title":"Clin Ther"}],"container-title":["High Blood Pressure &amp; Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-021-00450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-021-00450-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-021-00450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T05:16:02Z","timestamp":1675142162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-021-00450-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1007\/s40292-021-00450-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-59388\/v1","asserted-by":"object"}]},"ISSN":["1120-9879","1179-1985"],"issn-type":[{"value":"1120-9879","type":"print"},{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"assertion":[{"value":"21 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"E.S. reports receiving a grant from Sanofi Genzyme; positions on the advisory boards of Amicus and Sanofi Genzyme; speaker fees and travel support from Amicus, Sanofi Genzyme, and Shire-Takeda. H.P.M. reports receiving grants from Alexion, Amicus, Sanofi Genzyme, and Shire-Takeda. F.P. reports participations at advisory boards, speaker fees and travel support from Amicus, Sanofi Genzyme, and Shire-Takeda. F.R., H.E., A.B, L.R. and S.A. declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research was conducted in accordance with the World Medical Association Declaration of Helsinki and the institute\u2019s Ethics Committee (Comitato Etico Brianza) approved it (DREGC07006\/AGAL19211).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The dataset supporting the conclusions of this article is included within the article as additional file.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"FR conceived the research design, collected patients\u2019 data, performed the statistical analysis and wrote the manuscript first draft. HPM, ES and HE actively participated in the writing of the manuscript. FP performed the echocardiographic examination. AB, LR and SA collected patients\u2019 data during the clinical visits and implemented the database. HPM, ES and FP provided supervision and mentorship of FR during the drafting. All authors were involved in approving the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}